Literature DB >> 31370003

A high rate of modestly elevated plasma normetanephrine in a population referred for suspected PPGL when measured in a seated position.

Jessica Boyd1,2, Alexander A Leung3, Hossein Sm Sadrzadeh1,2, Christina Pamporaki4, Karel Pacak5, Timo Deutschbein6, Stephanie Fliedner7, Gregory A Kline3.   

Abstract

OBJECTIVE: Determine rate of high plasma normetanephrine or metanephrine (PNM-PMN) in a large sample of patients according to PNM-PMN posture and age-adjusted references.
DESIGN: Retrospective re-analysis of PNM-PMN from a Canadian reference laboratory (n = 5452), 2011-2015; most were in seated position (n = 5112) rather than supine (n = 340). An international PPGL database demonstrated expected distribution of supine PNM-PMN in PPGL patients.
METHODS: All PNM-PMN from a tertiary referral laboratory were reviewed. Any PNM-PMN result greater than 2× upper reference limit (URL) was considered likely true PPGL. Results 1-2× URL were uncertain, requiring additional testing/follow-up despite most being false positive given the rarity of PPGL. The rate of results in the 1-2× URL category were calculated for each group according to collection posture and differing published URL: seated, supine or supine age adjusted.
RESULTS: When collected and interpreted by seated URL, 19.6% of PNM required additional testing; only 4.6% being >2× URL. For patients over age 50 years, the abnormal rate was 24.9%. When collected supine, interpreted by supine age-adjusted URL, only 5.3% of PNM were mildly elevated. Possible false positives may be even lower when considering PMN or plasma methoxytyramine which were commonly high in true PPGL despite mild PNM elevations.
CONCLUSIONS: In a general medical population, seated PNM has a high rate of abnormal results, far exceeding expected prevalence. Supine measurement with supine, age-adjusted interpretation is strongly preferred prior to costly or invasive PPGL investigations.
SUMMARY: Review of 5452 plasma normetanephrine measurements showed 20% to be high, likely false positives for most. Supine, age-adjusted measures were half as likely to be elevated.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31370003      PMCID: PMC7446766          DOI: 10.1530/EJE-19-0176

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  21 in total

Review 1.  Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma.

Authors:  G Eisenhofer; T T Huynh; M Hiroi; K Pacak
Journal:  Rev Endocr Metab Disord       Date:  2001-08       Impact factor: 6.514

Review 2.  Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review.

Authors:  Roland Därr; Matthias Kuhn; Christoph Bode; Stefan R Bornstein; Karel Pacak; Jacques W M Lenders; Graeme Eisenhofer
Journal:  Endocrine       Date:  2017-04-12       Impact factor: 3.633

3.  Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites.

Authors:  Graeme Eisenhofer; Aleksander Prejbisz; Mirko Peitzsch; Christina Pamporaki; Jimmy Masjkur; Natalie Rogowski-Lehmann; Katharina Langton; Elena Tsourdi; Mariola Pęczkowska; Stephanie Fliedner; Timo Deutschbein; Felix Megerle; Henri J L M Timmers; Richard Sinnott; Felix Beuschlein; Martin Fassnacht; Andrzej Januszewicz; Jacques W M Lenders
Journal:  Clin Chem       Date:  2018-08-10       Impact factor: 8.327

Review 4.  Laboratory evaluation of pheochromocytoma and paraganglioma.

Authors:  Graeme Eisenhofer; Mirko Peitzsch
Journal:  Clin Chem       Date:  2014-10-20       Impact factor: 8.327

5.  Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma.

Authors:  Dirk Weismann; Mirko Peitzsch; Anna Raida; Aleksander Prejbisz; Maria Gosk; Anna Riester; Holger S Willenberg; Reiner Klemm; Georg Manz; Timo Deutschbein; Matthias Kroiss; Roland Därr; Martin Bidlingmaier; Andrzej Januszewicz; Graeme Eisenhofer; Martin Fassnacht
Journal:  Eur J Endocrinol       Date:  2014-12-01       Impact factor: 6.664

6.  Measurement of plasma free metanephrine and normetanephrine by liquid chromatography-tandem mass spectrometry for diagnosis of pheochromocytoma.

Authors:  Susan A Lagerstedt; Dennis J O'Kane; Ravinder J Singh
Journal:  Clin Chem       Date:  2004-01-15       Impact factor: 8.327

7.  Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?

Authors:  T J Cawood; P J Hunt; D O'Shea; D Cole; S Soule
Journal:  Eur J Endocrinol       Date:  2009-05-13       Impact factor: 6.664

8.  Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.

Authors:  Jacques W M Lenders; Quan-Yang Duh; Graeme Eisenhofer; Anne-Paule Gimenez-Roqueplo; Stefan K G Grebe; Mohammad Hassan Murad; Mitsuhide Naruse; Karel Pacak; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2014-06       Impact factor: 5.958

9.  Pheochromocytoma: state-of-the-art and future prospects.

Authors:  Emmanuel L Bravo; Rodrigo Tagle
Journal:  Endocr Rev       Date:  2003-08       Impact factor: 19.871

10.  Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: Can specificity be improved by adjustment for age?

Authors:  Anna M Sawka; Lehana Thabane; Amiram Gafni; Mitchell Levine; William F Young
Journal:  BMC Endocr Disord       Date:  2005-02-28       Impact factor: 2.763

View more
  4 in total

Review 1.  Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine.

Authors:  Svenja Nölting; Martin Ullrich; Jens Pietzsch; Christian G Ziegler; Graeme Eisenhofer; Ashley Grossman; Karel Pacak
Journal:  Cancers (Basel)       Date:  2019-10-08       Impact factor: 6.639

2.  A high sensitivity LC-MS/MS method for measurement of 3-methoxytyramine in plasma and associations between 3-methoxytyramine, metanephrines, and dopamine.

Authors:  Laura Smy; Mark M Kushnir; Elizabeth L Frank
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2021-08-05

Review 3.  How to Explore an Endocrine Cause of Hypertension.

Authors:  Jean-Baptiste de Freminville; Laurence Amar
Journal:  J Clin Med       Date:  2022-01-14       Impact factor: 4.241

Review 4.  Personalized Management of Pheochromocytoma and Paraganglioma.

Authors:  Svenja Nölting; Nicole Bechmann; David Taieb; Felix Beuschlein; Martin Fassnacht; Matthias Kroiss; Graeme Eisenhofer; Ashley Grossman; Karel Pacak
Journal:  Endocr Rev       Date:  2022-03-09       Impact factor: 19.871

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.